Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Steven Gary DuBois, M.D.

Co-Author

This page shows the publications co-authored by Steven DuBois and David Shulman.
Connection Strength

5.304
  1. Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. Cancer Med. 2021 Mar 09.
    View in: PubMed
    Score: 0.952
  2. The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. Paediatr Drugs. 2020 Apr; 22(2):189-197.
    View in: PubMed
    Score: 0.892
  3. Winning the RACE: Expanding pediatric cancer drug approvals. Pediatr Blood Cancer. 2019 08; 66(8):e27705.
    View in: PubMed
    Score: 0.829
  4. Derivation and validation of risk groups in patients with osteosarcoma utilizing regression tree analysis. Pediatr Blood Cancer. 2021 03; 68(3):e28834.
    View in: PubMed
    Score: 0.233
  5. Role of bone marrow biopsy for staging new patients with Ewing sarcoma: A systematic review. Pediatr Blood Cancer. 2021 02; 68(2):e28807.
    View in: PubMed
    Score: 0.233
  6. Landscape of phase 1 clinical trials for minors with cancer in the United States. Pediatr Blood Cancer. 2020 11; 67(11):e28694.
    View in: PubMed
    Score: 0.230
  7. Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center. Cancer Med. 2020 09; 9(18):6658-6666.
    View in: PubMed
    Score: 0.228
  8. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 10; 67(10):e28559.
    View in: PubMed
    Score: 0.228
  9. Sponsorship of oncology clinical trials in the United States according to age of eligibility. Cancer Med. 2020 07; 9(13):4495-4500.
    View in: PubMed
    Score: 0.224
  10. Second malignancies in patients treated for Ewing sarcoma: A systematic review. Pediatr Blood Cancer. 2019 11; 66(11):e27938.
    View in: PubMed
    Score: 0.213
  11. Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2019 Apr; 120(8):869.
    View in: PubMed
    Score: 0.208
  12. Timing of first-in-child trials of FDA-approved oncology drugs. Eur J Cancer. 2019 05; 112:49-56.
    View in: PubMed
    Score: 0.208
  13. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2018 08; 119(5):615-621.
    View in: PubMed
    Score: 0.199
  14. Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches. Sarcoma. 2018; 2018:1712964.
    View in: PubMed
    Score: 0.199
  15. Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. J Clin Oncol. 2021 Sep 30; JCO2101213.
    View in: PubMed
    Score: 0.062
  16. Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives. J Clin Med. 2021 Apr 14; 10(8).
    View in: PubMed
    Score: 0.060
  17. DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol. 2020 10; 33(10):1910-1921.
    View in: PubMed
    Score: 0.056
  18. Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies. Pediatr Blood Cancer. 2019 05; 66(5):e27595.
    View in: PubMed
    Score: 0.051
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.